Filing Flows

Filing Flows › 8-K events › Zymeworks

Zymeworks: entry into a material definitive agreement

Form 8-K filed Oct 23, 2026 · items 1.01, 7.01

FDA decisionsZymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

What the filing says

On October 22, 2026, Zymeworks Inc. and its subsidiary Zymeworks BC Inc. (together, the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, “Roche”), granting Roche exclusive rights to develop a

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Zymeworks at a glance

Latest quarterQ2 2026
Revenue$4.6M
Revenue Y/Y-91%
Operating margin-919.0%
IndustryPharmaceutical Preparations

Zymeworks, Q2 2026: revenue $4.6M (-91% year over year), operating margin -919.0%. The chart follows the revenue to costs, profit and cash.

Zymeworks: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.